Pediatric hodgkin lymphoma

Journal of Clinical Oncology

Volumn 33, Issue 27, 2015, Pages 2975-2985

  Mauz Körholz, Christine ^a   Metzger, Monika L ^b   Kelly, Kara M ^c   Schwartz, Cindy L ^d   Castellanos, Mauricio E ^e   Dieckmann, Karin ^f   Kluge, Regine ^g   Körholz, Dieter ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Unidad Nacional de Oncologia Pediatrica   (Guatemala)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; NEW DRUG; PROCARBAZINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; CHILDHOOD CANCER; DOSE DENSIFICATION; DRUG ELIMINATION; EVALUATION STUDY; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LOWEST INCOME GROUP; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; ADOLESCENT; COOPERATION; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; MASS COMMUNICATION; MORTALITY; ONCOLOGY; ONSET AGE; PEDIATRICS; SURVIVOR; TIME; TREATMENT OUTCOME; TRENDS;

ADOLESCENT; AGE OF ONSET; CHILD; COOPERATIVE BEHAVIOR; DIFFUSION OF INNOVATION; HODGKIN DISEASE; HUMANS; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; MEDICAL ONCOLOGY; PEDIATRICS; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84942274989     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.4853     Document Type: Review

References (108)

1. Schellong G, Bramswig J, Ludwig R, et al: Combined treatment strategy in over 200 children with Hodgkin's disease: Graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy - A report of the cooperative therapy study DAL-HD-82 [in German]. Klin Pädiatr 198: 137-146, 1986
2. Weiner MA, Leventhal BG, Marcus R, et al: Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol 9:1591-1598, 1991
3. Hutchinson RJ, Fryer CJ, Davis PC, et al: MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: Results of the Children's Cancer Group phase III trial. J Clin Oncol 16:897-906, 1998
4. Schellong G, Potter R, Bramswig J, et al: High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90 - The German-Austrian Pediatric Hodgkin's Disease study group. J Clin Oncol 17:3736-3744, 1999
5. Donaldson SS, Link MP, Weinstein HJ, et al: Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 25: 332-337, 2007
6. Devita VT, Jr, Serpick AA, Carbone PP: Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73:881-895, 1970
7. Smith MA, Rubinstein L, Anderson JR, et al: Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 17:569-577, 1999
8. Bhatia S, Robison LL, Oberlin O, et al: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334:745-751, 1996
9. Schellong G, Riepenhausen M, Ehlert K, et al: Breast cancer in young women after treatment for Hodgkin's disease during childhood or adolescence: An observational study with up to 33-year follow-up. Dtsch Arztebl Int 111:3-9, 2014
10. Kung FH, Schwartz CL, Ferree CR, et al: POG 8625: A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA1 Hodgkin Disease: A report from the Children's Oncology Group. J Pediatr Hematol Oncol 28:362-368, 2006
11. Schwartz CL, Constine LS, Villaluna D, et al: A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: The results of P9425. Blood 114:2051-2059, 2009
12. Schellong G, Hornig I, Bramswig J, et al: Significance of procarbazine in the chemotherapy of Hodgkin's disease: A report of the Cooperative Therapy Study DAL-HD-85 [in German]. Klin Pädiatr 200:205-213, 1988
13. Mauz-Körholz C, Hasenclever D, Dorffel W, et al: Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: The GPOH-HD-2002 study. J Clin Oncol 28:3680-3686, 2010
14. Mauz-Körholz C, Hasenclever D, Holzendorf V, et al: Feasibility of VECOPA: A dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin's Lymphoma - Results of the GPOH-HD-2002/VECOPA pilot trial. Leuk Lymphoma 10:1-17, 2014
15. Schellong GM: The German cooperative therapy studies. An approach to minimize treatment modalities and invasive staging procedures. Cancer Treat Res 41:277-289, 1989
16. Schellong G, Bramswig JH, Hornig-Franz I: Treatment of children with Hodgkin's disease: Results of the German Pediatric Oncology Group. Ann Oncol 3 Suppl 4:73-76, 1992
17. Dorffel W, Luders H, Ruhl U, et al: Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: Analysis and outlook. Klin Pädiatr 215: 139-145, 2003
18. Dorffel W, Ruhl U, Luders H, et al: Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: Final results of the multinational trial GPOH-HD95. J Clin Oncol 31:1562-1568, 2013
19. Vecchi V, Pileri S, Burnelli R, et al: Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age: An Italian (AIEOP) multicenter study on 215 patients. Cancer 72:2049-2057, 1993
20. Balwierz W, Moryl-Bujakowska A, Depowska T, et al: Over 30-year experience of Polish Pediatric Leukemia/Lymphoma Study Group for treatment of Hodgkin's disease in children and adolescents: Improvement curability and decrease of serious complications [in Polish]. Przegl Lek 61:33-39, 2004 (suppl 2)
21. Landman-Parker J, Pacquement H, Leblanc T, et al: Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before lowdose radiation therapy - Results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 18:1500-1507, 2000
22. Shankar AG, Ashley S, Atra A, et al: A limited role for VEEP (vincristine, etoposide, epirubicin, prednisolone) chemotherapy in childhood Hodgkin's disease. Eur J Cancer 34:2058-2063, 1998
23. Capra M, Hewitt M, Radford M, et al: Longterm outcome in children with Hodgkin's lymphoma: The United Kingdom Children's Cancer Study Group HD82 trial. Eur J Cancer 43:1171-1179, 2007
24. Shankar A, Visaduraki M, Hayward J, et al: Clinical outcome in children and adolescents with Hodgkin lymphoma after treatment with chemotherapy alone: The results of the United Kingdom HD3 national cohort trial. Eur J Cancer 48:108-113, 2012
25. Castellanos EM, Metzger ML, Fuentes S, et al: A Response-based ABVD regimen with or without radiotherapy for pediatric low and intermediate risk Hodgkin lymphoma in Central America and Dominican Republic: A report from AHOPCA. Pediatr Blood Cancer 59:977-978, 2012 (abstr O027)
26. Castellanos EM, Barrantes JC, Baez LF, et al: A chemotherapy only therapeutic approach to pediatric Hodgkin lymphoma: AHOPCA LH 1999. Pediatr Blood Cancer 61:997-1002, 2014
27. Pavlovsky S, Schvartzman E, Lastiri F, et al: Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease. J Clin Oncol 15:2652-2658, 1997
28. Appel B, Chen L, Hutchison RE, et al: Treatment of pediatric lymphocyte predominant Hodgkin lymphoma (LPHL): A report from the Children's Oncology Group. Klin Pädiatr 226:106, 2014 (abstr O-10)
29. Metzger ML, Weinstein HJ, Hudson MM, et al: Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA 307: 2609-2616, 2012
30. Friedmann AM, Hudson MM, Weinstein HJ, et al: Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. J Clin Oncol 20:3088-3094, 2002
31. Donaldson SS, Hudson MM, Lamborn KR, et al: VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: Results of a prospective clinical trial. J Clin Oncol 20:3081-3087, 2002
32. Hudson MM, Greenwald C, Thompson E, et al: Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 11:100-108, 1993
33. Hudson MM, Krasin M, Link MP, et al: Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol 22:4541-4550, 2004
34. Tebbi CK, Mendenhall N, London WB, et al: Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 46: 198-202, 2006
35. Tebbi CK, Mendenhall NP, London WB, et al: Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group. Pediatr Blood Cancer 59: 1259-1265, 2012
36. Weiner MA, Leventhal B, Brecher ML, et al: Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study J Clin Oncol 15:2769-2779, 1997
37. Nachman JB, Sposto R, Herzog P, et al: Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20:3765-3771, 2002
38. Kelly KM, Sposto R, Hutchinson R, et al: BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: A report from the Children's Oncology Group. Blood 117:2596-2603, 2011
39. Friedman DL, Chen L, Wolden S, et al: Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0031. J Clin Oncol 32:3651-3658, 2014
40. Appel BE, Chen L, Buxton A, et al: Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: A report from the Children's Oncology Group. Pediatr Blood Cancer 59:1284-1289, 2012
41. Körholz D, Wallace WH, Landman-Parker J: Euro-Net-Paediatric Hodgkin's Lymphoma Group (Euro-Net-PHL-C1): First international inter-group study for classical Hodgkin's lymphoma in children and adolescents. http://clinicaltrials.gov/ct/show/ NCT00433459:2012
42. Appel B, Chen L, Hutchison RE, et al: Treatment of pediatric lymphocyte predominant Hodgkin lymphoma (LPHL): A report from the Children's Oncology Group. J Clin Oncol 31:613s, 2013 (abstr 10000)
43. Burkhardt B, Körholz D, Klapper W, et al: Grey zone lymphoma in children and adolescents: Experience of pediatric Hodgkin and non-Hodgkin study groups. Klin Pädiatr 226:111, 2014 (abstr O-14)
44. Castellanos E, Peña A, Alabi S, et al: A risk-adapted, response-based therapeutic regimen using OEPA/COPDAC for the treatment of children with high-risk Hodgkin lymphoma, from the Central American y Dominican Republic Group. Klin Pädiatr 226:111, 2014 (abstr O-18)
45. Veron DA, Streitenberger P, García M, et al: Pediatric Hodgkin lymphoma through clinical trials in Argentina in the past 46 years: The GATLA experience. Klin Pädiatr 226:111, 2014 (abstr P-22)
46. Mittal R, Khalifa N, Khalifa S, et al: PET-based response-adapted treatment in pediatric HD can significantly reduce use of radiation therapy: A study from Kuwait Cancer Control Centre Kuwait. Klin Pädiatr 226:112, 2014 (abstr P-24)
47. Correles de Acquatella G, Garcia Guevara R, Montilva R, et al: BEACOPP protocol in 60 children with Hodgkin's lymphoma (HL): Multicenter experience in Venezuela. Klin Pädiatr 226:113, 2014 (abstr P-27)
48. Ahmad A, Asghar N, Taj M, et al: Challenges in treating Hodgkin lymphoma in a developing country: Children Hospital Lahore experience. Klin Pädiatr 226:114, 2014 (abstr P-33)
49. Kurch L, Hasenclever D, Tchavdarova L, et al: Impact of non-FDG-avid areas inside a tumour mass in paediatric Hodgkin lymphoma (PHL) patients. Klin Pädiatr 226:123, 2014 (abstr O-27)
50. McCarten K, Metzger M, Drachtman R, et al: Pleural effusion in intermediate Hodgkin lymphoma COG Protocol AHOD0031: Evolution with therapy and association with bulk mediastinal disease or bone, lung or pleural nodular disease. Klin Pädiatr 226:123, 2014 (abstr O-26)
51. Tebbi CK, London WB, Friedman D, et al: Dexrazoxane-associated risk for acute myeloid leukemia/ myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 25:493-500, 2007
52. Horning SJ, Hoppe RT, Breslin S, et al: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 20:630-637, 2002
53. Metzger ML, Billett AL, Friedmann AM, et al: Stanford V chemotherapy and involved field radiotherapy for children and adolescents with unfavorable risk Hodgkin lymphoma: Results of a multi-institutional prospective clinical trial. J Clin Oncol 30:606s, 2012 (abstr 9502)
54. Koontz MZ, Horning SJ, Balise R, et al: Risk of therapy-related secondary leukemia in Hodgkin lymphoma: The Stanford University experience over three generations of clinical trials. J Clin Oncol 31:592-598, 2013
55. Schellong G, Riepenhausen M, Bruch C, et al: Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 55:1145-1152, 2010
56. Hodgson DC, Dieckmann K, Terezakis S, et al: Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. Pract Radiat Oncol 5:85-92, 2015
57. Wolden SL, Chen L, Kelly KM, et al: Longterm results of ccg 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma: A report from the Children's Oncology Group. J Clin Oncol 30: 3174-3180, 2012
58. Keller F, Castellino S, Constine L, et al: Intensive therapy free survival (ITFS) for early-stage Hodgkin lymphoma (cHL) including chemotherapy and radiation therapy (IFRT) for recurrence after chemotherapy alone. Klin Pädiatr 226:105, 2014 (abstr O-09)
59. Raemaekers JM, Andre MP, Federico M, et al: Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188-1194, 2014
60. Engert A, Plutschow A, Eich HT, et al: Reduced treatment intensity in patients with earlystage Hodgkin's lymphoma. N Engl J Med 363:640- 652, 2010
61. von Tresckow B, Plutschow A, Fuchs M, et al: Dose-intensification in early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30:907-913, 2012
62. Olweny CL, Katongole-Mbidde E, Kiire C, et al: Childhood Hodgkin's disease in Uganda: A tenyear experience. Cancer 42:787-792, 1978
63. Jacobs P, King HS, Karabus C, et al: Hodgkin's disease in children: A ten-year experience in South Africa. Cancer 53:210-213, 1984
64. Ekert H, Waters KD, Smith PJ, et al: Treatment with MOPP or ChlVPP chemotherapy only for all stages of childhood Hodgkin's disease. J Clin Oncol 6:1845-1850, 1988
65. Sripada PV, Tenali SG, Vasudevan M, et al: Hybrid (COPP/ABV) therapy in childhood Hodgkin's disease: A study of 53 cases during 1989-1993 at the Cancer Institute, Madras. Pediatr Hematol Oncol 12:333-341, 1995
66. Arya LS, Dinand V, Thavaraj V, et al: Hodgkin's disease in Indian children: Outcome with chemotherapy alone. Pediatr Blood Cancer 46:26-34, 2006
67. Baez F, Ocampo E, Conter V, et al: Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol 8:247-250, 1997
68. Lobo-Sanahuja F, Garcia I, Barrantes JC, et al: Pediatric Hodgkin's disease in Costa Rica: Twelve years' experience of primary treatment by chemotherapy alone, without staging laparotomy. Med Pediatr Oncol 22:398-403, 1994
69. Ekert H, Fok T, Dalla-Pozza L, et al: A pilot study of EVAP/ABV chemotherapy in 25 newly diagnosed children with Hodgkin's disease. Br J Cancer 67:159-162, 1993
70. Sackmann-Muriel F, Bonesana AC, Pavlovsky S, et al: Hodgkin's disease in childhood: Therapy results in Argentina. Am J Pediatr Hematol Oncol 3:247-254, 1981
71. Sackmann-Muriel F, Zubizarreta P, Gallo G, et al: Hodgkin disease in children: Results of a prospective randomized trial in a single institution in Argentina. Med Pediatr Oncol 29:544-552, 1997
72. Castellanos EM, Metzger ME, Baez LF: A riskadapted, response-based therapeutic regimen using a modified Stanford V approach for the treatment of children with high-risk hodgkin lymphoma, AHOPCA LH 2004, a therapeutic regimen from the Central America and Dominican Republic Association of Pediatric Hematology Oncology. Blood 95:S19, 2010 (suppl 4; abstr P066)
73. Furth C, Amthauer H, Hautzel H, et al: Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma: Results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol 22:1198-1203, 2011
74. Meignan M, Gallamini A, Haioun C: Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 50:1257-1260, 2009
75. Meignan M, Gallamini A, Itti E, et al: Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 53:1876-1881, 2012
76. Cheson BD, Fisher RI, Barrington SF, et al: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 32: 3059-3068, 2014
77. Engert A, Haverkamp H, Kobe C, et al: Reducedintensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 noninferiority trial. Lancet 379:1791-1799, 2012
78. Juweid ME, Stroobants S, Hoekstra OS, et al: Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571-578, 2007
79. Hasenclever D, Kurch L, Mauz-Korholz C, et al: QPET : A quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging 41:1301-1308, 2014
80. Cho SY, McCarten K, Chen L, et al: 18F-FDG (FDG) PET five-point visual and quantitative SUV-based assessment and prognosis in pediatric Hodgkin lymphoma (HL): A preliminary retrospective analysis of Children's Oncology Group (COG) AHOD0031. Blood 120: 1530, 2012
81. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989
82. Luders H, Ruhl U, Marciniak H, et al: The impact of central review and central therapy planning on the treatment of children and adolescents with Hodgkin lymphoma. Eur J Cancer 50:425-433, 2014
83. Kurch L, Mauz-Korholz C, Bertling S, et al: The EuroNet Paediatric Hodgkin Network: Modern imaging data management for real time central review in multicentre trials. Klin Pädiatr 225:357-361, 2013
84. Purz S, Mauz-Korholz C, Korholz D, et al: [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. J Clin Oncol 29:3523-3528, 2011
85. Jaffe ES, Harris NL, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 111:S8-S12, 1999 (suppl 1)
86. Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D, et al: Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma: Experience from the European Network Group on Paediatric Hodgkin Lymphoma. Cancer 110:179-185, 2007
87. Nogova L, Reineke T, Eich HT, et al: Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16:1683-1687, 2005
88. Shankar A, Hall GW, Gorde-Grosjean S, et al: Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma: An Anglo-French collaborative report. Eur J Cancer 48:1700- 1706, 2012
89. Nogova L, Reineke T, Brillant C, et al: Lymphocyte-predominant and classical Hodgkin's lymphoma: A comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26:434-439, 2008
90. Rudiger T, Jaffe ES, Delsol G, et al: Workshop report on Hodgkin's disease and related diseases ("grey zone" lymphoma). Ann Oncol 9:31-38, 1998
91. Hartmann S, Eichenauer DA, Plutschow A, et al: The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group (GHSG). Blood 122:4246-4252, 2013; quiz 4292
92. Dunleavy K, Pittaluga S, Maeda LS, et al: Doseadjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.NEngl J Med 368:1408-1416, 2013
93. Fanale M, Fayad L, Pro B, et al: Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/ refractory Hodgkin lymphoma. Br J Haematol 154:284- 286, 2011
94. Horton TM, Drachtman RA, Chen L, et al: A phase II study of bortezomib with ifosfamide and vinorelbine in pediatric patients with refractory/recurrent Hodgkin disease (HD): A Children's Oncology Group (COG) study. J Clin Oncol 28, 2010 (abstr 9537)
95. Consortium. TAiCL: A Study of Panobinostat in Children with Refractory Hematologic Malignancies. https://clinicaltrials.gov/ct2/show/NCT01321346
96. Younes A, Gopal AK, Smith SE, et al: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30:2183-2189, 2012
97. Locatelli F, Neville K, Rosolen A, et al: Phase 1/2 Study of Brentuximab Vedotin in Pediatric Pts with Relapsed/ Refractory (R/R) Hodgkin Lymphoma (HL) or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 HL Data. Klin Pädiatr 226:117, 2014 (abstr O-20)
98. Younes A, Connors JM, Park SI, et al: Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study. Lancet Oncol 14:1348- 1356, 2013
99. Metzger M: Adcetris Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] with low dose tailored-field radiation therapy for unfavorable risk pediatric Hodgkin lymphoma NCT1920932. https://clinicaltrials.gov/ct2/show/ NCT01920932
100. Castellino SM; Children's Oncology Group: Brentuximab vedotin and combination chemotherapy in treating younger patients with newly diagnosed Hodgkin lymphoma NCT02166463. https://clinicaltrials.gov/ct2/show/NCT02166463
101. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311-319, 2015
102. Ma YP, van Leeuwen FE, Cooke R, et al: FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma. Blood 119:1029-1031, 2012
103. Haugsten EM, Wiedlocha A, Olsnes S, et al: Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 8:1439-1452, 2010
104. Best T, Li D, Skol AD, et al: Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med 17:941-943, 2011
105. Visscher H, Ross CJ, Rassekh SR, et al: Canadian Pharmacogenomics Network for Drug Safety Consortium. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 30:1422-1428, 2012
106. Schellong G, Hornig-Franz I, Rath B, et al: Reducing radiation dosage to 20-30 Gy in combined chemo-/ radiotherapy of Hodgkin's disease in childhood: A report of the cooperative DAL-HD-87 therapy study [in German]. Klin Pädiatr 206:253-262, 1994
107. Korholz D, Claviez A, Hasenclever D, et al: The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: Evolution in the tradition of the DAL/GPOH studies. Klin Padiätr 216:150-156, 2004
108. Viviani S, Zinzani PL, Rambaldi A, et al: ABVD versus BEACOPP for Hodgkin's lymphoma when highdose salvage is planned. N Engl J Med 365:203-212, 2011